 CRESSKILL, N.J. and JERUSALEM, March 01, 2021 GLOBE NEWSWIRE -- BrainsWay Ltd. NASDAQ TASE: BWAY BrainsWay or the Company, a global leader in the advanced noninvasive treatment of brain disorders, today announced the closing of its previously announced underwritten public offering of 5,315,300 American Depositary Shares ADSs, upsized to include 693,300 ADSs sold pursuant to the underwriters exercise in full of their option to purchase additional ADSs, at a price to the public of 8.50 per ADS. The gross proceeds to BrainsWay from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately 45.2 million. 